Technical Analysis for GNFT - GENFIT S.A.

Grade Last Price % Change Price Change
grade D 24.98 0.48% 0.12
GNFT closed up 0.48 percent on Thursday, April 18, 2019, on 37 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A N/A Flat
See historical GNFT trend table...

Date Alert Name Type % Chg
Inside Day Range Contraction 0.00%
Outside Day Range Expansion 0.48%
Inside Day Range Contraction -0.08%
New 52 Week High Strength -0.95%
NR7 Range Contraction 0.73%
Outside Day Range Expansion 0.32%
Spinning Top Other -1.30%
New 52 Week Closing High Bullish -2.61%
New 52 Week High Strength -2.61%
Gapped Up Strength -2.61%

Older signals for GNFT ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
GENFIT is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases. GENFIT concentrates its R&D efforts in areas of high unmet medical needs corresponding to a lack of approved treatments. GENFIT’s lead proprietary compound, elafibranor, is a drug candidate currently being evaluated in one of the most advanced Phase 3 studies worldwide (RESOLVE-IT) in nonalcoholic steatohepatitis, or NASH, considered by regulatory authorities as a medical emergency because it is silent, with potentially severe consequences, and with a prevalence on the rise. Elafibranor has also obtained positive preliminary results in a Phase 2 clinical trial in primary biliary cholangitis, or PBC, a severe chronic liver disease. As part of its comprehensive approach to clinical management of NASH patients, GENFIT is conducting an ambitious discovery and development program aimed at providing patients and physicians with a blood-based test for the diagnosis of NASH, i.e. non-invasive and easy-to-access. With facilities in Lille and Paris, France, and Cambridge, MA (USA), the Company has approximately 150 employees.
Medicine Biopharmaceutical Medical Specialties Autoimmune Diseases Hepatitis Hepatology Liver Liver Diseases Diagnostic Solutions Non Alcoholic Fatty Liver Disease Steatohepatitis Liver Disease Obeticholic Acid Primary Biliary Cholangitis
Is GNFT a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 1 bearish and 4 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 26.08
52 Week Low 20.805
Average Volume 247,092
200-Day Moving Average 0.0
50-Day Moving Average 0.0
20-Day Moving Average 0.0
10-Day Moving Average 24.998
Average True Range 0.9
ADX 0.0
+DI 33.9304
-DI 10.3787
Chandelier Exit (Long, 3 ATRs ) 23.38
Chandelier Exit (Short, 3 ATRs ) 23.505
Upper Bollinger Band 0.0
Lower Bollinger Band 0.0
Percent B (%b) 0.0
BandWidth 0.0
MACD Line 0.2526
MACD Signal Line 0.1432
MACD Histogram 0.1094
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 26.02
Resistance 3 (R3) 25.90 25.44 25.84
Resistance 2 (R2) 25.44 25.18 25.50 25.78
Resistance 1 (R1) 25.21 25.01 25.33 25.33 25.73
Pivot Point 24.75 24.75 24.81 24.81 24.75
Support 1 (S1) 24.52 24.49 24.64 24.64 24.23
Support 2 (S2) 24.06 24.32 24.12 24.18
Support 3 (S3) 23.83 24.06 24.12
Support 4 (S4) 23.95